SV2009003161A - Antagonistas de dii4 para el tratamiento de trastornos vasculares e isquemicos - Google Patents

Antagonistas de dii4 para el tratamiento de trastornos vasculares e isquemicos

Info

Publication number
SV2009003161A
SV2009003161A SV2009003161A SV2009003161A SV2009003161A SV 2009003161 A SV2009003161 A SV 2009003161A SV 2009003161 A SV2009003161 A SV 2009003161A SV 2009003161 A SV2009003161 A SV 2009003161A SV 2009003161 A SV2009003161 A SV 2009003161A
Authority
SV
El Salvador
Prior art keywords
organization
ischemical
antibody
ischemic
retinopathy
Prior art date
Application number
SV2009003161A
Other languages
English (en)
Inventor
Ivan B Lobov
Nicholas J Papadopoulos
Stanley J Wiegand
Original Assignee
Regeneron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma Inc filed Critical Regeneron Pharma Inc
Publication of SV2009003161A publication Critical patent/SV2009003161A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN AGENTE PARA INHIBiR LA ACTIVIDAD DEL LIGANDO 4 SIMILAR A DELTA (DII4) HUMANO, SE PROPORCIONA PARA EL TRATAMIENTO DE TRASTORNOS VASVULARES E ISQUEMICOS, PREFERIBLEMENTE, EL AGENTE ES UN ANTICUERPO ANTI-DII4 O FRAGMENTO DE ANTICUERPO CAPAZ DE INHIBIR LA UNIÓN DE DII4 A UN RECEPTOR NOTCH. EN UNA REALIZACIÓN, EL TRASTORNO ISQUÉMICO O VASCULAR ES UNA LESIÓN ISQUÉMICA, ISQUEMIA CEREBRAL, ISQUEMIA CARDIACA, AFECCIONES ISQUÉMICAS QUE AFECTAN A LAS EXTREMIDADES Y A OTRO ÓRGANOS O TEJIDOS, MALFORMACIONES ARTERIOVENOSAS, CICATRIZACIÓN DE HERIDAS, TRASPLANTE DE ÓRGANOS O TEJIDOS, INSUFICIENCIA PLACENTARIA, ESTRECHAMIENTO Y OCLUSIÓN ARTERIAL, ATEROSCLEROSIS, E HIPERTENSIÓN SISTÉMICA O PULMONAR. EN OTRA REALIZACIÓN, LA ENFERMEDAD TRATADA ES UNA ENFERMEDAD O AFECCIÓN OCULAR TAL COMO RETINOPATÍA DE LA PREMATURIDAD, RETINOPATÍA ISQUÉMICA, OCLUSIÓN VENOSA O ARTERIAL RETINIANA, RETINOPATÍA DIABÉTICA, NEOVASCULARIZACIÓN COROIDEA, DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD, NEOVASCULARIZACIÓN CORNEAL, GLAUCOMA NEOVASCULAR O TRASPLANTE DE CÓRNEA
SV2009003161A 2006-08-07 2009-02-05 Antagonistas de dii4 para el tratamiento de trastornos vasculares e isquemicos SV2009003161A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83600306P 2006-08-07 2006-08-07

Publications (1)

Publication Number Publication Date
SV2009003161A true SV2009003161A (es) 2010-02-01

Family

ID=38904599

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003161A SV2009003161A (es) 2006-08-07 2009-02-05 Antagonistas de dii4 para el tratamiento de trastornos vasculares e isquemicos

Country Status (33)

Country Link
US (1) US20080181893A1 (es)
EP (1) EP2054082B1 (es)
JP (1) JP5529536B2 (es)
KR (1) KR101497355B1 (es)
CN (1) CN101500605B (es)
AU (1) AU2007281916B2 (es)
BR (1) BRPI0716424B8 (es)
CA (1) CA2660235C (es)
CO (1) CO6150190A2 (es)
CR (1) CR10627A (es)
DK (1) DK2054082T3 (es)
ES (1) ES2398253T3 (es)
GT (1) GT200900029A (es)
HK (1) HK1137339A1 (es)
HR (1) HRP20130271T1 (es)
IL (1) IL196612A (es)
MA (1) MA30667B1 (es)
ME (1) ME00591B (es)
MX (1) MX2009000674A (es)
MY (1) MY150092A (es)
NO (1) NO341857B1 (es)
NZ (1) NZ574794A (es)
PL (1) PL2054082T3 (es)
PT (1) PT2054082E (es)
RS (1) RS52685B (es)
RU (1) RU2429876C2 (es)
SG (1) SG174033A1 (es)
SI (1) SI2054082T1 (es)
SV (1) SV2009003161A (es)
TN (1) TN2009000036A1 (es)
UA (1) UA95304C2 (es)
WO (1) WO2008019144A2 (es)
ZA (1) ZA200900337B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717431A2 (pt) 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
SG193209A1 (en) * 2008-09-10 2013-09-30 Genentech Inc Methods for inhibiting ocular angiogenesis
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
WO2011008641A1 (en) 2009-07-13 2011-01-20 Beth Israel Deaconess Medical Center, Inc. Methids of modulating angiogenesis and treatment of angiogenesis-related diseases
EP3029070A1 (en) 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
EP3680253A3 (en) * 2010-03-02 2020-09-30 AbbVie Inc. Therapeutic dll4 binding proteins
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
WO2014062659A2 (en) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US11679126B2 (en) 2016-11-17 2023-06-20 Chldren's Medical Center Corporation Methods to enhance microvascular engraftment of bioengineered and primary tissues
WO2023063842A1 (ru) 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
EP1928486A2 (en) * 2005-09-01 2008-06-11 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US20080014196A1 (en) 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development

Also Published As

Publication number Publication date
PL2054082T3 (pl) 2013-05-31
AU2007281916B2 (en) 2012-06-28
JP2010500355A (ja) 2010-01-07
HRP20130271T1 (hr) 2013-04-30
CA2660235A1 (en) 2008-02-14
AU2007281916A1 (en) 2008-02-14
ES2398253T3 (es) 2013-03-14
RU2429876C2 (ru) 2011-09-27
RU2009107921A (ru) 2010-09-20
ME00591A (en) 2011-12-20
EP2054082B1 (en) 2012-12-26
CO6150190A2 (es) 2010-04-20
SI2054082T1 (sl) 2013-04-30
ZA200900337B (en) 2009-12-30
MA30667B1 (fr) 2009-08-03
CN101500605B (zh) 2014-04-30
KR101497355B1 (ko) 2015-03-02
TN2009000036A1 (en) 2010-08-19
ME00591B (me) 2011-12-20
DK2054082T3 (da) 2013-01-21
RS52685B (en) 2013-08-30
CA2660235C (en) 2015-09-22
CN101500605A (zh) 2009-08-05
CR10627A (es) 2009-04-14
JP5529536B2 (ja) 2014-06-25
EP2054082A2 (en) 2009-05-06
BRPI0716424B8 (pt) 2021-05-25
GT200900029A (es) 2009-11-17
UA95304C2 (ru) 2011-07-25
WO2008019144A2 (en) 2008-02-14
NO20090984L (no) 2009-03-04
MY150092A (en) 2013-11-29
PT2054082E (pt) 2013-03-07
IL196612A0 (en) 2011-08-01
IL196612A (en) 2012-02-29
US20080181893A1 (en) 2008-07-31
MX2009000674A (es) 2009-02-04
BRPI0716424B1 (pt) 2018-06-26
KR20090039823A (ko) 2009-04-22
SG174033A1 (en) 2011-09-29
WO2008019144A3 (en) 2008-03-27
NZ574794A (en) 2011-06-30
NO341857B1 (no) 2018-02-12
HK1137339A1 (en) 2010-07-30
BRPI0716424A2 (pt) 2014-05-20

Similar Documents

Publication Publication Date Title
SV2009003161A (es) Antagonistas de dii4 para el tratamiento de trastornos vasculares e isquemicos
Arthur et al. Update on the role of alpha-agonists in glaucoma management
Xue et al. Posterior scleral reinforcement on progressive high myopic young patients
Browning Retinal vein occlusions: evidence-based management
JP2015509500A5 (es)
Duxbury et al. Successful treatment of central retinal artery thromboembolism with ocular massage and intravenous acetazolamide
JP6247009B2 (ja) 開瞼器
MX2022013665A (es) Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
Kazemi et al. Effect of topical phenylephrine 2.5% on episcleral venous pressure in normal human eyes
Pan et al. Effect of leukemia inhibitory factor on corneal nerve regeneration of rabbit eyes after laser in situ keratomileusis
Zeppieri et al. Beyond the Dusty Fog: Local Eye Drop Therapy and Potentially New Treatment Alternatives in Pseudoexfoliative Glaucoma
Deng et al. Corneal subbasal nerve fiber regeneration in myopic patients after laser in situ keratomileusis★
DOP2009000015A (es) Uso de antagonistas de dll4 para tratar trastornos oculares vasculares
Akpolat et al. Comparison of intravitreal bevacizumab alone versus combined bevacizumab and macular photocoagulation in diabetic macular edema
Murray et al. Asymmetric diabetic retinopathy associated with Fuchs’ heterochromic cyclitis
Zhalalova Rehabilitation and Treatment Algorithm for Patients with Ocular Ischemic Syndrome on the Background of Arterial Hypertension
Mortensen Corneal ectasia after PRK
JP2015027980A5 (es)
Nowroozzadeh Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis
Zavhorodnia et al. Efficiency of 0.005% latanoprost/0.5% timolol maleate fixed combinations, compared with 1% brinzolamide/0.5% timolol maleate in patients with primary open-angle glaucoma
Kahook 8 Sonic Effect on Aqueous Outflow
HU et al. Application progress of laser photocoagulation in diabetic retinopathy treatment in the era of anti-vascular endothelial growth factor agents
Karliychuk EFFICACY OF NEUROPROTECTIVE SUPPORT OF THE PATIENTS WITH DIABETES MELLITUS DURING PANRETINAL LASER PHOTOCOAGULATION
Vanathi Iatrogenic cataracts in ROP eyes
Khaqan et al. Lahore general hospital protocol for treatment of neovascular glaucoma caused by retinal disease